Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives. We are committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.

Voyager's Dinah Sah and Rob Kotin Honored Among PharmaVOICE 100 Most Inspiring People

Read the Press Release Read the Story From PharmaVOICE

September 3, 2014

Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer